ZP8396
Evidence Grade E — Very limited evidence. 3 published studies. 4 registered clinical trials.
Petrelintide is a long-acting amylin analogue from Zealand Pharma, competing with cagrilintide in the amylin space. It has a longer half-life (about 10 days versus 7) and is chemically stable without the tendency to form clumps — a manufacturing and safety advantage. Its primary strategic value is as a combination partner with GLP-1 drugs.
3 published studies: 3 human, 0 animal, 2 in-vitro, 1 reviews
Petrelintide is in Phase II development (not yet approved). Phase Ib results (48 patients, 16 weeks) showed up to 8.6% weight loss. No serious adverse events or anti-drug antibodies were detected. A Phase IIb trial is ongoing.
Petrelintide's primary strategic interest is as a potential partner for combination with GLP-1 agonists, similar to how cagrilintide is combined with semaglutide in CagriSema (#162). Zealand Pharma is also developing it in combination with survodutide.
Petrelintide activates amylin receptors and the calcitonin receptor, promoting satiety through brain pathways that complement GLP-1 signalling. Its chemical stability (no fibrillation tendency) differentiates it from native amylin and some analogues, which are prone to forming insoluble aggregates that complicate manufacturing and storage.
Phase Ib results (48 patients, 16 weeks) showed up to 8.6% weight loss with no serious adverse events. A collaboration with Roche pairs it with CT-388 (a GIP/GLP-1 agonist), while Zealand also plans to combine it with other compounds. Evidence is currently limited to early-phase data with small sample sizes. Phase IIb results (ZUPREME-1) are expected in the first half of 2026 and will be critical for determining the compound's viability. The chemical stability enabling easy formulation with partner drugs is a genuine technical advantage over cagrilintide. Whether the amylin-alone mechanism can compete with multi-target approaches remains uncertain.
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Liraglutide is marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for weight management (approved 2014). The LEADER trial, involving over 9,300 patients followed for nearly four years, established that liraglutide reduced the risk of major cardiovascular events by 13% — a landmark finding that helped establish GLP-1 treatments as a class with heart benefits. Saxenda is also approved for adolescents aged 12 and older. While historically significant, liraglutide has been substantially surpassed by newer agents. In a direct comparison, semaglutide achieved 15.8% weight loss compared to liraglutide's 6.4%. Liraglutide remains relevant as a lower-intensity option and as a benchmark against which newer treatments are measured. It has over a decade of real-world safety data, making it one of the best-understood medications in this class.
Setmelanotide is marketed as Imcivree (Rhythm Pharmaceuticals; approved November 2020 for POMC, PCSK1, or LEPR deficiency; June 2022 for Bardet-Biedl syndrome; December 2024 expanded to patients aged 2 years and older). Genetic testing confirming an eligible mutation is required before treatment. In patients with POMC or PCSK1 deficiency, approximately 80% achieved at least 10% weight loss in clinical trials. In Bardet-Biedl syndrome, 32.3% achieved the same threshold. The most common side effects are injection-site reactions and skin darkening (due to the melanocortin pathway's connection to pigmentation). Setmelanotide exemplifies precision medicine — it is highly effective in the specific genetic populations it targets but is not indicated for common obesity.
HGH Fragment 176-191 has no marketing authorisation. A Phase IIa trial in obesity (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. The clinical development programme was discontinued. The disconnect between animal data (which showed significant fat reduction in obese mice) and the failed human trial is the defining feature of this compound's development history. Products available through unregulated channels lack pharmaceutical quality assurance. The failed Phase II trial represents the highest level of clinical evidence available.
